Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Non Operating Income (2016 - 2026)

Amphastar Pharmaceuticals has reported Other Non Operating Income over the past 13 years, most recently at $515000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 82.55% year-over-year to $515000.0; the TTM value through Dec 2025 reached $23000.0, down 99.44%, while the annual FY2025 figure was $23000.0, 99.44% down from the prior year.
  • Other Non Operating Income for Q4 2025 was $515000.0 at Amphastar Pharmaceuticals, up from $231000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $13.3 million in Q3 2021 and troughed at -$5.5 million in Q4 2023.
  • A 5-year average of $1.2 million and a median of $406500.0 in 2024 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: tumbled 262.38% in 2023 and later skyrocketed 1618.21% in 2024.
  • Year by year, Other Non Operating Income stood at $2.9 million in 2021, then rose by 15.58% to $3.4 million in 2022, then tumbled by 262.38% to -$5.5 million in 2023, then skyrocketed by 153.83% to $3.0 million in 2024, then plummeted by 82.55% to $515000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for AMPH at $515000.0 in Q4 2025, $231000.0 in Q3 2025, and $1.5 million in Q2 2025.